Day: April 28, 2025

WASHINGTON, April 28, 2025 (GLOBE NEWSWIRE) — FTI Consulting, Inc. (NYSE: FCN) today announced the appointment of Josh Harris as a Senior Managing Director in the Private Equity practice within the firm’s Corporate Finance & Restructuring segment. Mr. Harris, who is based in New York, brings nearly 20 years of experience partnering with private equity firms, portfolio companies and corporate clients to unlock value across the entire deal lifecycle — from diligence and acquisition to transformation, growth and exit. Mr. Harris has specific expertise in the areas of portfolio strategy, performance improvement, post-merger integration and organizational restructuring. In his role at FTI Consulting, Mr. Harris will focus on developing and implementing large-scale transformations involving change management and operational design...

SARASOTA, FL, April 28, 2025 (GLOBE NEWSWIRE) — Silo Pharma, Inc. (Nasdaq: SILO) (“Silo” or the “Company”), a developmental stage biopharmaceutical company focused on novel therapeutics and drug delivery systems, today announced the filing of a patent application with the U.S. Patent and Trademark Office (USPTO) focused on the neurology drug SPC-14, an intranasal compound for the treatment of Alzheimer’s disease (AD) exclusively licensed to Silo Pharma from Columbia University.  The patent, titled “Compositions and Methods for the Treatment of Alzheimer’s Disease and Other Neurogenerative Disease,” covers SPC-14’s novel mechanism of action for targeting glutamate receptor NDMAR and serotonin 5-HT4 to address cognitive and neuropsychiatric symptoms in AD. By targeting the two receptor molecules, the drug has shown efficacy against...

SLINGERLANDS, N.Y., April 28, 2025 (GLOBE NEWSWIRE) — Plug Power Inc. (NASDAQ: PLUG), a global leader in comprehensive hydrogen solutions, today announced it has signed a definitive agreement for a secured debt facility and achieved key operational and financial milestones that support its path toward profitability and long-term growth. Up to $525 Million Yorkville Credit Facility and Retirement of Dilutive Debenture Plug has signed a definitive agreement for a secured debt facility with Yorkville Advisors providing for the issuance of up to $525 million of secured debentures. The facility includes an initial $210 million tranche, which will be fully funded at the initial closing and additional tranches of up to $315 million. The initial tranche is expected to close on or around May 2, 2025. With the net proceeds from the initial...

New patents provide additional composition of matter and methods of use claims, strengthening the protection for liquid oral taste-masked reformulation, LIKMEZ New subject matter listed in the U.S. Food and Drug Administration’s (“FDA”) Orange Book HALIFAX, Nova Scotia, April 28, 2025 (GLOBE NEWSWIRE) — Appili Therapeutics Inc. (TSX: APLI; OTCPink: APLIF) (the “Company” or “Appili”), a biopharmaceutical company focused on drug development for infectious diseases and medical countermeasures, today announced the United States Patent and Trademark Office and the Mexican Patent Office have granted new patent claims protecting its oral formulation of metronidazole, LIKMEZ®™. The newly granted patents include:U.S. patent no. 20230086660A1 – Oral Formulations of Metronidazole and Methods of Treating an Infection...

Albertslund, 28th April 2025 Brødrene A & O Johansen A/S acquires leading e-commerce domain “VVS-eksperten.dk” with effect from 1 January 2026 Brødrene A & O Johansen A/S has today entered into an agreement to acquire the domain VVS-eksperten.dk, one of Denmark’s leading online platforms for plumbing and heating products. The acquisition further strengthens AO’s position in the Danish online market and complements the company’s already strong digital platform. VVS-eksperten.dk has established itself as a trusted destination for private consumers seeking a wide selection of plumbing and heating articles at competitive prices. The acquisition supports AO’s continued investment in digital growth and customer-centric online solutions. We look forward to continuing to service VVS-eksperten’s customers on a new VVS-eksperten.dk webshop...

MELBOURNE, Australia and SAN FRANCISCO, April 28, 2025 (GLOBE NEWSWIRE) — Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative diseases, today announced that David Stamler, M.D., Chief Executive Officer presented the ATH434-201 Phase 2 clinical trial results at the annual MSA Research Symposium hosted by University College London, Institute of Neurology in partnership with the MSA Trust of the U.K. “We were honoured to be selected to present the recent data from our double-blind Phase 2 trial,” said, Dr. Stamler. “The Symposium brought together prominent clinicians and researchers from both Europe and the US along with industry scientists, all of whom are focused on increasing their understanding of MSA and...